Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment to reduce the risk of cardiovascular disease in people living with elev
Ionis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with cardiovascular disease that it hopes will entice Novartis into a licensing deal.
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.